Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRB Spruce Biosciences, Inc.

Trading 04-02 13:54:10 EDT

70.46

+0.93

+1.33%

High71.00	Low67.50	Vol27.95K
Open69.53	D1 Closing69.53	Amplitude5.03%
Mkt Cap96.66M	Tradable Cap59.94M	Total Shares1.37M
T/O1.95M	T/O Rate3.29%	Tradable Shares850.80K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SPRB","market":"US","secType":"STK","nameCN":"Spruce Biosciences, Inc.","latestPrice":70.455,"timestamp":1775152421651,"preClose":69.53,"halted":0,"volume":27954,"delay":0,"changeRate":0.013303609952538431,"floatShares":850800,"shares":1372000,"eps":-50.829998,"marketStatus":"Trading","change":0.925,"latestTime":"04-02 13:54:10 EDT","open":69.53,"high":71,"low":67.5,"amount":1949676.7488300002,"amplitude":0.050338,"askPrice":70,"askSize":18,"bidPrice":68,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-50.829998,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1775160000000},"marketStatusCode":2,"adr":0,"listingDate":1602216000000,"exchange":"NASDAQ","adjPreClose":69.53,"preHourTrading":{"tag":"盘前","latestPrice":67.03,"preClose":69.53,"latestTime":"08:51 EDT","volume":19,"amount":1339.86993,"timestamp":1775134290436,"change":-2.5,"changeRate":-0.035956,"amplitude":0.056091},"postHourTrading":{"tag":"盘后","latestPrice":69.53,"preClose":69.53,"latestTime":"19:04 EDT","volume":147,"amount":10222.9698,"timestamp":1775084676636,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.099625,"impliedVol":0.883,"impliedVolPercentile":0.9885},"requestUrl":"/m/hq/s/SPRB","defaultTab":"news","newsList":[{"id":"2621752165","title":"BRIEF-Spruce Biosciences On March 16, Entered Termination Agreement With Kaken Pharmaceutical - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621752165","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621752165?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:42","pubTimestamp":1774042965,"startTime":"0","endTime":"0","summary":"BRIEF-Spruce Biosciences On March 16, Entered Termination Agreement With Kaken Pharmaceutical - SEC FilingMarch 20  - SEC Filing:SPRUCE BIOSCIENCES INC - ON MARCH 16, ENTERED TERMINATION AGREEMENT WITH KAKEN PHARMACEUTICAL - SEC FILINGSPRUCE BIOSCIENCES INC - COLLABORATION AGREEMENT WITH KAKEN PHARMACEUTICAL TO TERMINATE EFFECTIVE MARCH 31, 2026 - SEC FILINGSPRUCE BIOSCIENCES INC - ALL LICENSES & RIGHTS GRANTED BY CO TO KAKEN TO BE TERMINATDE; NO UNEARNED MILESTONE PAYMENTS OR ROYALTIESSource text: [ID:n0001193125-26-117888]Further company coverage: SPRB.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN4080Y9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621752969","title":"Spruce Biosciences Ends Kaken Collaboration, Refocuses Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2621752969","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621752969?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:33","pubTimestamp":1774042427,"startTime":"0","endTime":"0","summary":"Spruce Biosciences ( ($SPRB) ) has issued an update. On March 16, 2026, Spruce Biosciences agreed with Kaken Pharmaceutical to terminate their Janu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/spruce-biosciences-ends-kaken-collaboration-refocuses-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/spruce-biosciences-ends-kaken-collaboration-refocuses-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621675424","title":"Spruce Biosciences Inc - Collaboration Agreement With Kaken Pharmaceutical to Terminate Effective March 31, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621675424","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621675424?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:08","pubTimestamp":1774040918,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN4080Y9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621475475","title":"Spruce Biosciences Inc - All Licenses & Rights Granted by Co to Kaken to Be Terminatde; No Unearned Milestone Payments or Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2621475475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621475475?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:08","pubTimestamp":1774040918,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN4080Y9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621542667","title":"Spruce Biosciences FY2025 R&D expenses fell 57.97% to USD 19.5 million, net loss was USD 39 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621542667","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621542667?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:05","pubTimestamp":1774040735,"startTime":"0","endTime":"0","summary":"Spruce published a Form 8-K reporting full-year 2025 results and corporate updates, including that a BLA submission for TA-ERT in MPS IIIB is expected in Q4 2026 after FDA Type B meetings.Cash and cash equivalents were USD 48.9 million as of Dec. 31, 2025, excluding USD 15.0 million in gross proceeds from an Avenue Capital loan facility; the company said cash is expected to fund its operating plan into early 2027.R&D expenses fell 58.02% to USD 19.5 million, primarily due to stopping tildacerfont development in CAH, partly offset by TA-ERT development and the acquisition of SPR202.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL8jvvSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618958722","title":"Spruce Biosciences Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2618958722","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618958722?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:53","pubTimestamp":1773147180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2026 08:53 ET (12:53 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618932457","title":"Spruce Biosciences Price Target Maintained With a $200.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618932457","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618932457?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:29","pubTimestamp":1773142140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2026 07:29 ET (11:29 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618352049","title":"Spruce Biosciences price target lowered to $170 from $180 at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2618352049","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618352049?lang=en_us&edition=fundamental","pubTime":"2026-03-10 17:40","pubTimestamp":1773135619,"startTime":"0","endTime":"0","summary":"Citizens lowered the firm’s price target on Spruce Biosciences (SPRB) to $170 from $180 and keeps an Outperform rating on the shares. The firm cont...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-price-target-lowered-to-170-from-180-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-price-target-lowered-to-170-from-180-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618832623","title":"Rpt-Spruce Biosciences FY Net Income USD -38.966 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618832623","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618832623?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:36","pubTimestamp":1773056201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX10G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618628762","title":"Spruce Biosciences Inc - to Offer and Sell Common Stock up to $75 Mln Through Jefferies - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618628762","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618628762?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:32","pubTimestamp":1773055976,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX0UY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618993628","title":"Spruce Biosciences Inc - May Offer and Sell Common Stock up to Maximum Program Amount Under Sales Agreement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618993628","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618993628?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:24","pubTimestamp":1773055479,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX10F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618628994","title":"Spruce Biosciences Inc - Enters Open Market Sale Agreement With Jefferies Llc on March 9, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618628994","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618628994?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:24","pubTimestamp":1773055479,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX10F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618289256","title":"BRIEF-Spruce Biosciences Reports Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618289256","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618289256?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:24","pubTimestamp":1773055469,"startTime":"0","endTime":"0","summary":"BRIEF-Spruce Biosciences Reports Full Year 2025 Financial ResultsMarch 9 (Reuters) - Spruce Biosciences SPRB.O:SPRUCE BIOSCIENCES FY NET INCOME USD -38.966 MILLIONSPRUCE BIOSCIENCES FY INCOME FROM OPE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nPLX579C05:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618288436","title":"Spruce Biosciences 2025 net loss narrows, secures $50 mln funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2618288436","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618288436?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:14","pubTimestamp":1773054873,"startTime":"0","endTime":"0","summary":"Spruce Biosciences 2025 net loss narrows, secures $50 mln fundingOverviewBiopharmaceutical firm's net loss for 2025 decreased compared to 2024Company secured up to $50 mln in growth capital from Avenu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL1N3ZX0EY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4231","BK4080","BK4139","BRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618664076","title":"Spruce Biosciences FY 2025 R&D expenses fall 58% to USD 19.52 million, net loss narrows 27% to USD 38.97 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618664076","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618664076?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:05","pubTimestamp":1773054325,"startTime":"0","endTime":"0","summary":"Spruce Biosciences reported a FY 2025 net loss of USD 38.97 million, narrowing 27%. R&D expenses fell 58% to USD 19.52 million, while G&A expenses rose 16% to USD 16.99 million. Total operating expenses decreased 40% to USD 36.51 million. Cash and cash equivalents were USD 48.91 million at year-end, and the company said it expects its cash to fund its current operating plan into early 2027. Spruce said it plans to submit a BLA for tralesinidase alfa  in MPS IIIB in Q4 2026 and cited positive Type B meeting feedback from the FDA supporting a potential accelerated approval pathway based on a surrogate endpoint.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDLcfkyWl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618640021","title":"Spruce Biosciences Inc - Expects Cash and Cash Equivalents to Fund Current Operating Plan Into Early 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640021","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640021?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:05","pubTimestamp":1773054300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUABQK9RF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618020640","title":"Spruce Biosciences Inc - Bla Submission for Ta-Ert for Treatment of Sanfilippo Syndrome Type B (Mps Iiib) on Track for Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618020640","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618020640?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:05","pubTimestamp":1773054300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUABQK9RF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618823623","title":"Spruce Biosciences Inc - Net Loss $39.0 Mln for Year Ended Dec 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2618823623","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618823623?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:05","pubTimestamp":1773054300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nPLX579C05:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618064076","title":"Press Release: Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2618064076","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618064076?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:05","pubTimestamp":1773054300,"startTime":"0","endTime":"0","summary":"Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B  on Track for the Fourth Quarter of 2026. Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company's Commercial Capabilities in Preparation for a Potential Launch of TA-ERT. Secured up to $50 Million in Growth Capital from Avenue Capital Group. Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate updates.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930227.SGD","LU1880398554.USD","LU1267930813.SGD","LU0072461881.USD","LU0889566641.SGD","BK4099","LU0310800965.SGD","03160","BK4588","BK4585","BK4175","LU0052756011.USD","SG9999001440.SGD","BK4139","LU0211327993.USD","LU0154236417.USD","BK4555","LU0128525689.USD","LU0162691827.USD","LU0310799852.SGD","LU0211328371.USD","BK6045","LU1267930490.SGD","LU0792757196.USD","LABU","BK4604","LU0006061336.USD","CAH","LU1571399168.USD","SPRB","PA3.SI","TM","LU1880398471.USD","BK6512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618640900","title":"Spruce Biosciences names Dale Hooks chief commercial officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640900","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640900?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054042,"startTime":"0","endTime":"0","summary":"Spruce Biosciences appointed Dale Hooks as chief commercial officer. Hooks previously served as chief commercial officer at Applied Therapeutics and held senior commercial roles at Reata Pharmaceuticals and Clovis Oncology. He also held commercial leadership positions at Genentech, Galderma, Novartis, and Glaxo Wellcome.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire  on March 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL2c4tHw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505439.SGD","IE00BWDBJ516.SGD","LU0161305163.EUR","BK4588","LU0211331839.USD","LU0889565916.HKD","LU0985481810.HKD","LU1309081286.SGD","LU1098665638.USD","LU0971552830.HKD","IE00B19Z9P08.USD","LU0203347892.USD","LU0058720904.USD","LU1015430645.USD","LU1645745479.HKD","LU0109394709.USD","LU1670756490.USD","BIIB","SPRB","GSK.UK","LU0321505868.SGD","LU0545562505.USD","IE00B19Z9Z06.USD","BK4585","LU1035777561.USD","LU0109981661.USD","BK4139","LU0575583348.USD","LU1228905037.USD","BK4532","LU1400636491.USD","LU1202635105.USD","LU1228905540.USD","LU0320765992.SGD","IE00B3T34201.USD","LU0203345920.USD","LU0971552673.USD","LU1064927863.SGD","LU1983299246.USD","LU0225284248.USD","BK4533","IE0034235071.USD","LU0289739699.SGD","IE00B894F039.SGD","LU0306807586.USD","LU1400636574.HKD","LU0234570918.USD","LU1302929846.USD","LU1046248800.SGD","LU1481599808.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sprucebiosciences.com","stockEarnings":[{"period":"1week","weight":-0.0063},{"period":"1month","weight":0.2827},{"period":"3month","weight":-0.2018},{"period":"6month","weight":6.8832},{"period":"1year","weight":258.1502},{"period":"ytd","weight":-0.2018}],"compareEarnings":[{"period":"1week","weight":-0.0024},{"period":"1month","weight":-0.0454},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0209},{"period":"1year","weight":0.168},{"period":"ytd","weight":-0.0391}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.190445},{"month":2,"riseRate":0.5,"avgChangeRate":-0.036118},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.209049},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.16314},{"month":5,"riseRate":0.4,"avgChangeRate":-0.03765},{"month":6,"riseRate":0.4,"avgChangeRate":-0.079875},{"month":7,"riseRate":0.6,"avgChangeRate":0.089441},{"month":8,"riseRate":0.4,"avgChangeRate":0.028537},{"month":9,"riseRate":0.4,"avgChangeRate":-0.136102},{"month":10,"riseRate":0.4,"avgChangeRate":2.105377},{"month":11,"riseRate":0.5,"avgChangeRate":0.001192},{"month":12,"riseRate":0.333333,"avgChangeRate":0.217863}],"exchange":"NASDAQ","name":"Spruce Biosciences, Inc.","nameEN":"Spruce Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Spruce Biosciences, Inc.(SPRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Spruce Biosciences, Inc.,SPRB,Spruce Biosciences, Inc.股票,Spruce Biosciences, Inc.股票老虎,Spruce Biosciences, Inc.股票老虎国际,Spruce Biosciences, Inc.行情,Spruce Biosciences, Inc.股票行情,Spruce Biosciences, Inc.股价,Spruce Biosciences, Inc.股市,Spruce Biosciences, Inc.股票价格,Spruce Biosciences, Inc.股票交易,Spruce Biosciences, Inc.股票购买,Spruce Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Spruce Biosciences, Inc.(SPRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction